TickerFacts.

AIM ImmunoTech Inc. (AIM): Long-Term Debt

Annual figures by period end, from SEC filings.

$4.48M
As of 2025-12-31
$3.62M
As of 2026-06-30
+16.3%
5-year compound annual growth
2018-12-31: $2.52M2019-12-31: $2.32M2020-12-31: $2.11M2024-12-31: $2.81M2025-12-31: $4.48M$4.48M
2018-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$4.48M+59.5%2026-03-27, Balance as of period end
2024-12-31$2.81Mn/a2026-03-27, Balance as of period end
No annual figure between 2020-12-31 and 2024-12-31.
2020-12-31$2.11M-9.1%2021-03-31, Balance as of period end
2019-12-31$2.32M-7.9%2020-03-30, Balance as of period end
2018-12-31$2.52Mn/a2019-04-01, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
AIM ImmunoTech Inc. (AIM)2025-12-31$4.48M+59.5%
Inmune Bio, Inc. (INMB)2024-12-31$15.00Mn/a
Humacyte, Inc. (HUMA)2025-12-31$35.44Mn/a
TScan Therapeutics, Inc. (TCRX)2025-12-31$32.53M+1.4%
Alector, Inc. (ALEC)2025-12-31$10.00M0.0%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$75.00M0.0%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%

Compare AIM, INMB, HUMA, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗